Abstract
Multiple myeloma (MM) is an incurable disease characterized by the proliferation of end-stage B lymphocytes (plasma cells, PCs). As a consequence of myeloma growth in the bone marrow, a number of signaling pathways are activated that trigger malignant PC proliferation, escape from apoptosis, migration, and invasion. Thanks to new insights into the molecular pathogenesis of MM, novel approaches aimed at targeting these abnormally activated cascades have recently been developed and others are under study. These strategies include the inhibition of membrane receptor tyrosine kinases, inhibition of the proteasome/aggresome machinery, inhibition of histone deacetylases, inhibition of farnesyltransferases, targeting of molecular chaperones, and others. We will herein review and discuss these novel biological approaches with particular emphasis on those based on biochemical pathways which drive cell signaling. By providing the rationale for innovative therapeutic strategies, the above mechanisms represent targets for new compounds being tested in the management of this disease.
Similar content being viewed by others
References
Ludwig H (2005) Advances in biology and treatment of multiple myeloma. Ann Oncol 16(Suppl 2):ii106–ii112
Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362–1369
Harousseau JL (2005) Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol 17(2):93–98
Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24(6):929–936
Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20(22):4420–4427
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609–2617
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487–2498
Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2(3):175–187
Bakkus MH, Heirman C, Van Riet I, Van Camp B, Thielemans K (1992) Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 80(9):2326–2335
Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546–1558
Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575
Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R (2001) Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 98(10):3082–3086
Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH et al (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86(11):4250–4256
Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108(5):1724–1732
Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cells 9(4):313–325
Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Davila R, Gonzalez-Paz N et al (2003) Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 17(2):427–436
Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98(7):2229–2238
Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al (2006) The molecular classification of multiple myeloma. Blood 108(6):2020–2028
Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23(26):6333–6338
Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745–1757
Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O’Connor SM et al (2003) Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102(13):4504–4511
Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S et al (2005) Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 24(15):2461–2473
Duhrsen U, Hossfeld DK (1996) Stromal abnormalities in neoplastic bone marrow diseases. Ann Hematol 73(2):53–70
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93(5):1658–1667
Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC (2004) Focus on multiple myeloma. Cancer Cells 6(5):439–444
Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N et al (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98(20):11581–11586
Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13):3527–3533
Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S et al (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100(6):2195–2202
Zannettino AC, Farrugia AN, Kortesidis A, Manavis J, To LB, Martin SK et al (2005) Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65(5):1700–1709
Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494
Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E et al (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106(9):3160–3165
Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC (1995) CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 85(7):1903–1912
Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87(3):1104–1112
Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20(33):4519–4527
Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 95(8):2630–2636
Franchimont N, Rydziel S, Canalis E (2000) Transforming growth factor-beta increases interleukin-6 transcripts in osteoblasts. Bone 26(3):249–253
Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL et al (1997) IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 159(5):2212–2221
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1–20
Hideshima T, Nakamura N, Chauhan D, Anderson KC (2001) Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20(42):5991–6000
Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A et al (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85(3):765–771
Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, Chioetto G et al (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108(5):1698–1707
Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S et al (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175–3184
Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A (1989) Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74(4):1266–1273
Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC (2001) The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 20(33):4519–4527
Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K et al (2004) VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 104(9):2886–2892
Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T et al (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98(2):428–435
Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D et al (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21(37):5673–5683
Qiang YW, Kopantzev E, Rudikoff S (2002) Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99(11):4138–4146
Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R et al (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res 63(18):5850–5858
Qiang YW, Yao L, Tosato G, Rudikoff S (2004) Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells. Blood 103(1):301–308
Gazitt Y, Akay C (2004) Mobilization of myeloma cells involves SDF-1/CXCR4 signaling and downregulation of VLA-4. Stem Cells 22(1):65–73
Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B (1998) Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 103(4):1152–1160
Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115(2):369–378
Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690–698
Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM (2004) Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10(11):1187–1189
Ishikawa H, Tsuyama N, Abroun S, Liu S, Li FJ, Taniguchi O et al (2002) Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6. Blood 99(6):2172–2178
Li FJ, Tsuyama N, Ishikawa H, Obata M, Abroun S, Liu S et al (2005) A rapid translocation of CD45RO but not CD45RA to lipid rafts in IL-6-induced proliferation in myeloma. Blood 105(8):3295–3302
Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4):301–310
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–759
Bharti AC, Shishodia S, Reuben JM, Weber D, Alexanian R, Raj-Vadhan S et al (2004) Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103(8):3175–3184
Feinman R, Koury J, Thames M, Barlogie B, Epstein J, Siegel DS (1999) Role o f NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. Blood 93(9):3044–3052
Shen J, Channavajhala P, Seldin DC, Sonenshein GE (2001) Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J Immunol 167(9):4919–4925
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T et al (2002) Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 99(11):4079–4086
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 173(3):699–703
Deng L, Ding W, Granstein RD (2003) Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol 121(5):1060–1065
D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082–4085
Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL et al (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102(24):8567–8572
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565–1571
Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al (2001) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 98(2):492–494
Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol 40(4 Suppl 4):3–7
Barlogie B, Zangari M, Spencer T, Fassas A, Anaissie E, Badros A et al (2001) Thalidomide in the management of multiple myeloma. Semin Hematol 38(3):250–259
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354(10):1021–1030
Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M et al (2005) Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23(23):5334–5346
Anderson KC (2003) The role of immunomodulatory drugs in multiple myeloma. Semin Hematol 40(4 Suppl 4):23–32
Richardson P, Anderson K (2004) Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 22(16):3212–3224
Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al (2006) A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108:3458–3464
Bartlett JB, Tozer A, Stirling D, Zeldis JB (2005) Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 93(6):613–619
Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050–4053
Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23(21):4776–4789
Ciechanover A, Orian A, Schwartz AL (2000) Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22(5):442–451
Ciechanover A (2005) Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 6(1):79–87
Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28(6):613–619
Elliott PJ, Ross JS (2001) The proteasome: a new target for novel drug therapies. Am J Clin Pathol 116(5):637–646
Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61(7):3071–3076
LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N et al (2002) Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62(17):4996–5000
Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG et al (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165–172
Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615–2622
Rajkumar SV, Richardson PG, Hideshima T, Anderson KC (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23(3):630–639
Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD (2004) Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 23(11):2009–2015
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19):16639–16647
Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al (2001) Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61(9):3535–3540
Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R et al (2004) Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 104(8):2458–2466
Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A et al (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102(1):303–310
Sayers TJ, Murphy WJ (2006) Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol Immunother 55(1):76–84
Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS (2005) The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther 4(3):443–449
Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D et al (2005) A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res 65(18):8350–8358
Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M et al (2005) A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib. Cancer Cells. 8(5):407–419
Chauhan D, Catley L, Li G, Hideshima T, Richardson P, Palladino M et al (2005) Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma. J Clin Oncol (ASCO Annual Meeting Proceedings) 23(16S):3122
Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101(3):1053–1062
Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K (2003) Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene 22(54):8797–8801
Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al (2003) Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res 63(1):18–21
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X et al (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89(9):3345–3353
Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R et al (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21(12):2326–2334
Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC et al (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59(5):1041–1048
Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D et al (2002) Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther 1(10):851–860
Rousselot P, Larghero J, Labaume S, Poupon J, Chopin M, Dosquet C et al (2004) Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol 72(3):166–171
Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A et al (2002) Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 16(9):1835–1837
Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R (2004) Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. Br J Haematol 125(4):470–476
Hu J, Fang J, Dong Y, Chen SJ, Chen Z (2005) Arsenic in cancer therapy. Anticancer Drugs 16(2):119–127
Berenson JR, Swift RA, Ferretti D, Purner MB (2004) A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 5(2):130–134
Borad MJ, Swift R, Berenson JR (2005) Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma. Leukemia 19(1):154–156
Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A et al (2004) A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia 18(9):1518–1521
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M et al (2004) Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cells 5(3):221–230
Menu E, Jernberg-Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O et al (2006) Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 107(2):655–660
Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M et al (2006) IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 107(2):669–678
Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM (2005) Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 105(1):317–323
Hu L, Shi Y, Hsu JH, Gera J, Van Ness B, Lichtenstein A (2003) Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 101(8):3126–3135
Le Gouill S, Pellat-Deceunynck C, Harousseau JL, Rapp MJ, Robillard N, Bataille R et al (2002) Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 16(9):1664–1667
Ochiai N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E et al (2003) Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 102(9):3349–3353
Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH, Lichtenheld MG (2003) Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk Lymphoma 44(12):2123–2134
Bolick SC, Landowski TH, Boulware D, Oshiro MM, Ohkanda J, Hamilton AD et al (2003) The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 17(2):451–457
Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A et al (2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 101(5):1692–1697
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T et al (2004) Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103(9):3271–3277
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE et al (2005) Anti-myeloma activity of heat shock protein-90 inhibition. Blood 107(3):1092–1100
David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S (2005) The combination of the Farnesyl transferase inhibitor (Lonafarnib) and the proteasome inhibitor (Bortezomib) induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106(13):4322–4329
van de Donk NW, Lokhorst HM, Nijhuis EH, Kamphuis MM, Bloem AC (2005) Geranylgeranylated proteins are involved in the regulation of myeloma cell growth. Clin Cancer Res 11(2 Pt 1):429–439
Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW (2005) Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol 130(6):912–925
Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T et al (2002) Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem 277(10):7875–7881
Vacca A, Ribatti D (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20(2):193–199
Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E et al (2002) The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62(17):5019–5026
Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T et al (2004) GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103(9):3474–3479
Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, Lancet J et al (2004) Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10(1 Pt 1):88–95
Wang S, El-Deiry WS (2003) TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22(53):8628–8633
Gazitt Y (1999) TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13(11):1817–1824
Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R et al (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98(3):795–704
Gomez-Benito M, Balsas P, Bosque A, Anel A, Marzo I, Naval J (2005) Apo2L/TRAIL is an indirect mediator of apoptosis induced by interferon-alpha in human myeloma cells. FEBS Lett 579(27):6217–6222
Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S (2005) PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105(3):1280–1287
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM et al (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16(3):260–264
Paterson JL, Li Z, Wen XY, Masih-Khan E, Chang H, Pollett JB et al (2004) Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol 124(5):595–603
Trudel S, Ely S, Farooqi Y, Affer M, Robbiani DF, Chesi M et al (2004) Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 103(9):3521–3528
Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N et al (2005) FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 24(56):8259–8267
Trudel S, Stewart AK, Rom E, Wei E, Li ZH, Kotzer S et al (2006) The inhibitory anti-FGFR3 antibody, PRO-001 is cytotoxic to t(4;14) multiple myeloma cells. Blood 7:7
Peterson CL, Laniel MA (2004) Histones and histone modifications. Curr Biol 14(14):R546–R551
Piazza F, Semenzato G (2004) Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. Expert Rev Anticancer Ther 4(3):387–400
Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6(1):38–51
Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137–168
Lavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68(3):170–178
Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 101(10):4055–4062
Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101(2):540–545
Khan SB, Maududi T, Barton K, Ayers J, Alkan S (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 125(2):156–161
Pei XY, Dai Y, Grant S (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10(11):3839–3852
Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761–772
Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99(22):14374–14379
Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT et al (2004) p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23(54):8766–8776
Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q (2006) Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107(6):2432–2439
Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA et al (1996) Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood 87(5):1928–1938
Kroning H, Tager M, Thiel U, Ittenson A, Reinhold D, Buhling F et al (1997) Overproduction of IL-7, IL-10 and TGF-beta 1 in multiple myeloma. Acta Haematol 98(2):116–118
Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM (1999) Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol 66(6):981–988
Abildgaard N, Glerup H, Rungby J, Bendix-Hansen K, Kassem M, Brixen K et al (2000) Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 64(2):121–129
Wright N, de Lera TL, Garcia-Moruja C, Lillo R, Garcia-Sanchez F, Caruz A et al (2003) Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 102(6):1978–1984
Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M et al (2004) Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res 10(22):7540–7546
Acknowledgements
We are grateful to all the members of the Unit of Hematological Malignancies at VIMM and of the Hematology-Immunology Section at Padua University Hospital for support and suggestions. We thank M. E. Donach for reading the manuscript. Work in G.S. Lab is supported by grants from the International Myeloma Foundation (to F.A.P.), from the Associazione Italiana per la Ricerca sul Cancro (AIRC) and Istituto Oncologico Veneto (IOV).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Piazza, F.A., Gurrieri, C., Trentin, L. et al. Towards a new age in the treatment of multiple myeloma. Ann Hematol 86, 159–172 (2007). https://doi.org/10.1007/s00277-006-0239-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-006-0239-5